Tower Research Capital (TRC)’s Ascentage Pharma AAPG Stock Holding History

Tower Research Capital (TRC)’s Portfolio AAPG Stock Details AAPG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-518	Closed	-$12.4K	–	5763
2026 Q1	$12.4K	Buy	518 +288	+125%	+$7.09K	﹤0.01%	3794
2025 Q4	$6.04K	Sell	230 -599	-72%	-$19.6K	﹤0.01%	4084
2025 Q3	$32.4K	Buy	+829	New	+$33.6K	﹤0.01%	2877

Other funds holding AAPG

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Tower Research Capital (TRC)'s AAPG Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Ascentage Pharma (AAPG) in Q2 2026, closing a stake of 518 shares — an estimated $12.4K sold.

Tower Research Capital (TRC) first reported a position in AAPG in Q3 2025 and held it in 3 quarters. The position peaked at $32.4K in Q3 2025. 8 funds tracked by Wall St. Rank hold AAPG as of Q2 2026.

Tower Research Capital (TRC) reported no remaining Ascentage Pharma position as of Q2 2026 after selling out during the quarter.
Tower Research Capital (TRC) sold 518 Ascentage Pharma shares in Q2 2026, an estimated $12.4K.
Tower Research Capital (TRC) first reported a position in Ascentage Pharma in Q3 2025 and held it in 3 quarters.
Tower Research Capital (TRC)'s Ascentage Pharma position peaked at $32.4K in Q3 2025.
8 funds tracked by Wall St. Rank held Ascentage Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.